Take advantage of automated and closed system enrichment of monocytes and blood dendritic cells (DCs) with the CliniMACS Prodigy® Platform. Combined with our MACS® GMP Products, this is all you need for consistent and reliable cell products.
The preparation of cellular monocyte-derived dendritic cell (Mo-DC) products for clinical settings comprises several independent processing steps including density gradient centrifugation, monocyte separation, cell culture (differentiation and maturation), and possibly electroporation. To meet the increasing regulatory requirements for cell-based therapeutics, we have integrated all manufacturing steps in a closed system operated by an automated cell processing instrument, the CliniMACS Prodigy® with CliniMACS® Electroporator.
Scientific poster
Monocyte-derived dendritic cells (Mo-DCs) generated with CliniMACS Prodigy® are functional and fulfill requirements for cancer vaccines
Mareke Brüning, Tobias Ozimkowski, Eva Bergschneider, Michael Birth, Stefan Wild, and Andrzej Dzionek, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany
Brochure
Manufacturing dendritic cell products for clinical research
This comprehensive brochure provides information regarding next generation clinical-grade production of DCs that may allow optimization of cellular products, formulation, and efficacy.
Recent reports suggest that simultaneous activation of different DC subsets may have a synergistic effect that can increase anti-tumor responses. We have established the idea of a new clinical approach based on primary DCs derived from peripheral blood using the CliniMACS Prodigy System. The CliniMACS Prodigy CD1c/CD304 Enrichment and Activation System enables fully automated production of BDC-based vaccines with high purities and recoveries.
Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. For complete regulatory notes, please click here.
